What You Will Learn

Please join Carterra at our upcoming symposium in San Francisco, CA.

You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Machine Learning and AI Approaches for Protein Engineering
Emerging Targets for Oncology and Beyond
Engineering Bispecific and Multifunctional Antibodies
Biophysical Characterization and High-Definition Epitope Binning Enabling Novel Biotherapeutics

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

Companies presenting in 2025:

Agenda	Symposium co-hosted by Curia
9:45 – 10:00 AM	Arrive and Check-in
10:00 – 10:30 AM	Networking and Coffee/Tea
10:30 – 10:45 AM	Symposium Begins—Welcome
10:45 – 11:15 AM	Lequn Zhao, PhD, Head of Biologics Discovery, Attovia Therapeutics HT-SPR and Therapeutic Attobody Discovery
	Awaiting Abstract
11:15 – 11:45 AM	Karanbir Pahil, PhD, Investigator, GSK High-Throughput SPR in DNA-Encoded Library Screening and Hit Validation
	Abstract: DNA-encoded libraries (DELs) enable drug discovery chemists to identify thousands of hits from screening campaigns using billions of molecules, producing a vast array of small molecule structure-activity relationship data and potentially interesting chemical matter that needs to be triaged efficiently. DELs are made combinatorically, with every library member being assigned a unique DNA barcode, and every step of chemistry being compatible with the presence of DNA. Here, we show how we leverage the facility of resynthesizing DEL screening hits with DNA tags and the Carterra LSA^® platform to enable high throughput binding assays.
11:45 AM - 1:00 PM	Lunch and Networking
1:00 – 1:30 PM	Yadong Yu, PhD, Senior Research Scientist III, Curia VHH Antibody Discovery for huCD200R1
	Abstract: Nanobodies are a growing modality in antibody therapeutics, with FDA-approved treatments driving demand for VHH discovery. Their small size and typically longer CDR3 enables targeting challenging epitopes in solid tumors, overcoming limitations of larger antibodies. Here we used single B cell antibody discovery to rapidly identify a diverse set of potent, high affinity, neutralizing VHH from immunized llamas against CD200R1, an emerging therapeutic immune checkpoint target.
1:30 – 2:00 PM	James Fishburn, Senior Scientist, Pfizer HT-SPR Evaluation of Critical Reagent Antibodies Yields Expected and Unexpected Benefits
	Abstract: Antibody-drug conjugates (ADCs) are an important and growing class of oncologic therapeutics that have the potential for a broad therapeutic index and reduced immunogenicity in patients. These metrics are closely monitored in clinical trials using bioanalytical methods that employ critical reagents, which are frequently ADC-specific anti-idiotype (anti-ID) antibodies. At Pfizer, we utilize a Carterra LSA to evaluate our reagent candidates to ensure that there is accurate and specific detection of our ADCs. This process allows us to comprehensively understand the binding characteristics of each anti-ID, which subsequently guides our selection of the anti-ID reagents for use in the pharmacokinetic and immunogenicity assays of our experimental ADCs. This presentation details our evaluation methodology and its advantages, and shares an unexpected discovery of cooperatively binding anti-IDs that was enabled by the LSA.
2:00 – 2:30 PM	Dan Bedinger, PhD, Sr. Manager Field Application Science, Carterra Applications from mAbs to Fragment Screening: How Carterra LSA, LSA^XT and Ultra HT-SPR Platforms Enable Highly Parallel Analysis Advancing All Drug Discovery Modalities
	Abstract: Carterra’s HT-SPR technology platforms have set the bar for throughput and scalability for biologics discovery and now extend to small molecule and fragment screening. The Carterra Ultra enables a transformative approach to library screening, highly parallel analysis, where many targets can be screened simultaneously against a library. Why run single campaigns when you can screen your entire target backlog simultaneously? This presentation will highlight three interesting application examples: the detailed kinetic characterization of human Fab fragments directly from bacterial extracts, the profiling of binding of TCRs to arrays of immobilized pMHCs, and fragment library screening.
2:30 PM	Symposium Ends

What You Will Learn

Register Here

Agenda